# ELI-002 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/eli-002

> ELI-002, sponsored by Elicio Therapeutics, Inc. (ELTX): 13 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ELI-002 |
| Codes | ELI-002 |
| Sponsor | Elicio Therapeutics, Inc. (ELTX) https://sec-api.dev/companies/eltx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-31, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001601485-26-000056): "In October 2023, we completed enrollment of the AMPLIFY-7P Phase 1 portion of the trial for ELI-002 7P and initiated enrollment of the AMPLIFY-7P Phase 2 portion of the trial in January 2024." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000056/eltx-20260630.htm
- SEC Form 10-K (accession 0001601485-26-000027): "In October 2023, we completed enrollment of the AMPLIFY-7P Phase 1 portion of the trial for ELI-002 7P and initiated enrollment of the AMPLIFY-7P Phase 2 portion of the trial in January 2024." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm
- SEC Form 10-K (accession 0001601485-25-000049): "In October 2023, we completed enrollment of the AMPLIFY-7P Phase 1 portion of the trial for ELI-002, our 7-peptide formulation, and initiated enrollment of the AMPLIFY-7P Phase 2 portion of the trial in January 2024." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm

### Jan 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-31, last confirmed 2025-03-31.
- SEC Form 10-K (accession 0001601485-25-000049): "We initiated enrollment of the Phase 2 of the AMPLIFY-7P trial in January 2024 and we have not yet initiated clinical trials for any other product candidates." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-01-23.
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000074): "We are pleased to have strengthened our balance sheet, and such funding is expected to support operations into Q2 2025, beyond the anticipated AMPLIFY-7P interim analysis."" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/q3earnings_prx11-12x24xf.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000074): "We continue to anticipate completion of enrollment in Q4 2024 and expect to conduct a pre-planned interim analysis, including DFS, in H1 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/q3earnings_prx11-12x24xf.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000009): "the timing of the availability of data from our clinical trials, including the DFS interim analysis anticipated from the Phase 2 trial of ELI-002 7P anticipated in the first half of 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148525000009/eliciocorporatedeck_0123.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000009): "ELI-002 7P Phase 2 trial: Disease-free survival interim analysis expected in H1 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148525000009/eliciocorporatedeck_0123.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-269400): "Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival (DFS) expected in H1 2025" https://www.sec.gov/Archives/edgar/data/1601485/000119312524269400/d858884dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000009): "$33M in new capital raised - expected to fund the Company into Q2 2025 beyond the anticipated Phase 2 interim analysis" https://www.sec.gov/Archives/edgar/data/1601485/000160148525000009/eliciocorporatedeck_0123.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000006): "Our ongoing Phase 2 AMPLIFY-7P study, which is fully enrolled, remains on track for a pre-planned interim data analysis in H1 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/fdatypebpr_final.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "7P Phase 2 trial disease-free survival interim analysis expected in H1 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/eliciocorporatedeck_dece.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "interim analysis expected in 1H 2025 Phase 2ELI-002 7PELI-002 Randomized Phase 2 PDAC, n=135 patients 2:1 Randomized, Open Label Study with 10 DFS endpoint" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/eliciocorporatedeck_dece.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "As we continue working to bring this potentially transformative off-the-shelf vaccine to cancer patients, we look forward to the interim analysis of the randomized Phase 2 portion of AMPLIFY-7P, expected in the first half of 2025."" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/esmoiopresentationproof_.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "the timing of the availability of data from Elicio's clinical trials, including interim analysis of the randomized Phase 2 portion of the AMPLIFY-7P trial, expected in the first half of 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/esmoiopresentationproof_.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "$33M in new capital raised - Company funded into the second quarter of 2025 past anticipated Phase 2 interim analysis" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/eliciocorporatedeck_dece.htm

### May 13, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-05-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000072): "Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival ("DFS") in randomized Phase 2 AMPLIFY- 7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration ("FDA") on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate and clinical updates." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm

### Q3 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-03-31, last confirmed 2025-06-04.
- SEC Form 10-Q (accession 0001601485-25-000074): "This study is progressing toward a disease-free survival event-driven interim analysis expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000074/angn-20250331.htm
- SEC Form 10-K (accession 0001601485-25-000049): "A disease-free survival event-driven interim analysis is expected in Q3 2025, depending on rate of event accrual." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000096): "the timing of the availability of data from Elicio's clinical trials, including the interim analysis from the Phase 2 AMPLIFY-7P trial expected in the third quarter of 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a991eliciodebttransactio.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000072): "the timing of the availability of data from Elicio's clinical trials, including the DFS event-driven interim analysis, from the Phase 2 AMPLIFY-7P trial expected in the third quarter of 2025" https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000096): "Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a991eliciodebttransactio.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000096): "The proceeds from the Note Financing, together with Elicio's current cash and cash equivalents, are expected to support Elicio's operations into the first quarter of 2026, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/a991eliciodebttransactio.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000072): "DFS event-driven interim analysis of Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm
- SEC Form 10-K (accession 0001601485-25-000049): "The Phase 2 DFS event-driven interim analysis is expected in Q3 2025, depending on rate of event accrual." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm

### August 7, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-08-07, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000108): "Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival ("DFS") expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, August 7, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate and clinical updates." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/a2025-08x07xxeltxxx2q25f.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-05-13, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000072): "The Company expects that its current cash and cash equivalents will support operations into Q4 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm

### Oct 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-11-13, last confirmed 2026-03-12.
- Press release filed with the SEC (EX-99) (accession 0001601485-25-000123): "Responses were observed across all seven mKRAS epitopes and occurred across a diverse HLA background, highlighting ELI-002 7P's potential to benefit a broad and genetically diverse patient population.  In October 2025, Elicio announced robust T cell responses across diverse HLA backgrounds in the ongoing Phase 2 AMPLIFY-7P trial.  In September 2025, Elicio announced the planned investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P in resectable and borderline resectable PDAC led by Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, assessing ELI-002 7P combined with mFOLFIRINOX with or without the anti-PD-1 antibody." https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/elicioq325prdraft_111320.htm
- SEC Form 10-K (accession 0001601485-26-000027): "In September 2025, we announced an Investigator-Initiated Phase 1 Trial ("IIT") to be conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in PDAC." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000027/angn-20251231.htm

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-12-12, last confirmed 2024-12-12.
- Press release filed with the SEC (EX-99) (accession 0001601485-24-000107): "the timing of initiation of our planned clinical trials, including the initiation of an ELI-002 Phase 1B in colorectal cancer, the initiation of ELI-002 combination studies, and our anticipated Phase 3 readiness in the first quarter of 2026" https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/eliciocorporatedeck_dece.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-03-12, last confirmed 2026-03-12.
- Press release filed with the SEC (EX-99) (accession 0001601485-26-000026): "In 2025, Elicio continued advancement of the randomized Phase 2 AMPLIFY-7P trial in post-resection mKRAS PDAC, with the event-driven primary DFS analysis remaining on track for an anticipated 1H 2026 readout" https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/elicioq425prdraft_31226.htm

### August 13, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001601485-26-000055): "Announced the activation of an investigator-initiated Phase 1 neoadjuvant trial evaluating ELI-002 7P plus chemotherapy and an anti-PD-1 checkpoint inhibitor in borderline resectable and resectable pancreatic ductal adenocarcinoma ("PDAC")." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm

### Q4 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001601485-26-000055): ""Our recent financing provided us with the capital needed to evaluate initial data from our planned Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor, which is anticipated to begin in the fourth quarter of this year." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001601485-26-000055): "Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026" https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm
- Press release filed with the SEC (EX-99) (accession 0001601485-26-000055): "Initiation of the Phase 1 combination trial for ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer anticipated in Q4 2026 Second Quarter 2026 Financial Results R&D expense for the second quarter of 2026 was $6.8 million, compared to $7.0 million for the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm
- SEC Form 10-Q (accession 0001601485-26-000056): "In addition, based on preliminary post-study observations suggesting that ELI-002 7P-induced immune responses may enhance sensitivity to checkpoint inhibition, we announced our intention to initiate a Phase 1 study evaluating ELI-002 7P in combination with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic mKRAS pancreatic cancer, which we anticipate initiating in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1601485/000160148526000056/eltx-20260630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/eli-002.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ELI-002 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/eli-002

```bibtex
@misc{secapidev_pdufa_eli_002_20261116,
  title        = {ELI-002 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/eli-002}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_eli_002_20261116","title":"ELI-002 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/eli-002","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
